Poziotinib: all 21 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedNCT04172597Phase 2Results posted
• A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedNCT03744715Phase 2Results posted
• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT03318939Phase 2Results posted
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedNCT02659514Phase 2Results posted
• A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedNCT05378763Phase 3
• Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung CancerWithdrawnNCT05045404Phase 2
• Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsCompletedNCT04436562Phase 1
• Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT04044170Phase 2
• A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)Status unknownNCT03770988Phase 2
• A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedNCT03429101Phase 1
• Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2
• Poziotinib in EGFR Exon 20 Mutant Advanced NSCLCTerminatedNCT03066206Phase 2
• Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedNCT02979821Phase 2
• A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR PathwayCompletedNCT02544997Phase 2
• Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed RegimensCompletedNCT02418689Phase 2
• Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing TherapyStatus unknownNCT02216916Phase 2
• NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung AdenocarcinomaTerminatedNCT01819428Phase 2
• A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerCompletedNCT01746771Phase 1/2
• NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase InhibitorsCompletedNCT01718847Phase 2
• Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid TumorsCompletedNCT01455584Phase 1
• Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid TumorsCompletedNCT01455571Phase 1

← Poziotinib overview